Engaging Researchers
to Advance Efforts
The NHLBI’s Investment
The Initiative complements the National Heart, Lung, and Blood Institute (NHLBI)’s investment in sickle cell disease research, which includes basic, clinical, translational, and implementation science research. The Cure Sickle Cell Initiative does not replace ongoing research efforts; rather, it complements them. The NHLBI continues to fund research conducted by investigators focusing on sickle cell disease.
Working Together as a Community
The Cure Sickle Cell Initiative has included people from various scientific disciplines—basic and clinical researchers, statisticians, data scientists, geneticists, clinical trialists, and others. An important element of the Initiative is working together as a community to accelerate research by avoiding duplication of efforts, leveraging evolving knowledge, and integrating best practices from government, academia, and industry.
Efforts are focused on key priorities: creating biological and clinical endpoints, developing data resources, evaluating the risk of clonal hematopoiesis and myelodysplastic syndromes, addressing long-term follow-up, and engaging patients through outreach.